Health Technology Assessment
Subscribe (RSS)
Results 1 - 20 of 188
-
Technology Reports
-
Technology Reports
Robot-assisted Surgery versus Open Surgery and Laparoscopic Surgery: Clinical Effectiveness and Economic Analyses
September 21, 2011
Report Summary A few Canadian hospitals have developed surgical robotics programs using technology such as the Da Vinci® Surgical System, to help surgeons perform surgery. This technology is however associated with significant capital and operating costs. Given the relatively recent introduction...
-
Technology Reports
Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis
March 9, 2011
The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted a review to evaluate the cost-effectiveness of Octaplas® against standard frozen plasma and its budgetary impact to the health system. Report Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitt...
-
Technology Reports
Vancomycin or Metronidazole for Treatment of Clostridium difficile Infection: Clinical and Economic Analyses
January 26, 2011
This report focuses on first-line treatment using vancomycin or metronidazole for initial or recurrent moderate to severe Clostridium difficile infection. Clinical, economic, and health services impact considerations are evaluated. Report This report has been extensively peer-reviewed by ...
-
Technology Reports
Clopidogrel versus Other Antiplatelet Agents: A CADTH Technology Assessment Report Series
November 26, 2010
This series of three health technology assessments examines the clinical and cost-effectiveness of Clopidogrel (alone or in combination with acetylsalicylic acid i.e., ASA) versus other antiplatelet agents (ASA, ticlopidine, dipyridamole, extended-release dipyridamole 200 mg/ASA 25 mg combinatio...
-
Technology Reports
-
Technology Reports
-
Technology Reports
Pharmacologic-based Strategies for Smoking Cessation
September 21, 2010
Smoking is one of the major risk factors for cancer, respiratory disease, and cardiovascular disease. Smoking tobacco is a risk factor that can be changed — by quitting permanently. Unfortunately, quitting smoking is much easier said than done. So how can we best help smokers to quit? Which of...
-
Technology Reports
Bariatric Surgery for Severe Obesity: Systematic Review and Economic Evaluation
September 20, 2010
The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted a systematic review and primary economic evaluation to assess the clinical effectiveness, cost-effectiveness, and health services impact of bariatric surgery procedures for the management of severe obesity. Report This ...
-
Technology Reports
Ablation Procedures for Rhythm Control in Patients With Atrial Fibrillation: Clinical and Cost-Effectiveness Analyses
September 17, 2010
Atrial fibrillation (AF) is a type of heart rhythm disturbance or arrhythmia that affects over 200,000 Canadians, including more than 5% of the population over the age of 65. The most common type of arrhythmia, AF is associated with a high degree of morbidity and mortality, including an increased ri...
-
Technology Reports
-
Technology Reports
Triple Therapy for Moderate-to-Severe Chronic Obstructive Pulmonary Disease
May 5, 2010
The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted a systematic review and primary economic evaluation to evaluate the clinical effectiveness, cost-effectiveness, and health services impact of triple therapy in the treatment of moderate-to-severe chronic obstructive p...
-
Technology Reports
Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease
March 29, 2010
The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted a systematic review to evaluate the clinical, economic and budgetary implications of pulmonary rehabilitation (PR) programs to assist policy-makers and health care providers with future decisions in the establishment and ...
-
Technology Reports
-
Technology Reports
Recombinant Activated Factor VII for Prevention of Bleeding Unrelated to Hemophilia: Clinical and Economic Systematic Review
February 4, 2010
CADTH’s health technology assessment report examines the clinical efficacy and cost-effectiveness of off-label use of recombinant activated factor VII (rFVIIa), an agent currently approved to control bleeding in patients with either hemophilia A or B and clotting factor inhibitors. &nb...
-
Technology Reports
Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses
December 22, 2009
CADTH’s health technology assessment report on clopidogrel versus other antiplatelet agents examines the clinical efficacy and cost-effectiveness of this treatment strategy for secondary prevention of vascular events in adults with cerebrovascular disease. The report also assesses cur...
-
Technology Reports
Addendum to the Canadian Agency for Drugs and Technologies in Health Guidelines for the Economic Evaluation of Health Technologies: Specific Guidance for Oncology Products
December 22, 2009
This addendum to CADTH’s Guidelines for the Economic Evaluation of Health Technologies (3rd Edition) is intended to provide specific guidance on the methods used to conduct high-quality economic evaluations of oncology products. The oncology-specific guidelines should be considered a comp...
-
Technology Reports
Portable Monitoring Devices for Diagnosis of Obstructive Sleep Apnea at Home: Review of Accuracy, Cost-Effectiveness, Guidelines, and Coverage in Canada
December 9, 2009
An amendment to this report to reflect the inclusion of additional portable monitoring devices that are licensed in Canada has been made. The revised report is now available. View Report (38 pages) View Executive Summary (3 pages) Context and Policy Issues Obstructive sleep apnea...
-
Technology Reports
Reassessment of Health Technologies: Obsolescence and Waste
December 4, 2009
CADTH’s report on the reassessment of health technologies is intended to inform and encourage further discussion about the appropriate use of existing health technologies. This report considers practical and policy issues related to health technology obsolescence and proposes a framework f...
-
Technology Reports
Long-Acting Beta2-Agonist and Inhaled Corticosteroid Combination Therapy for Adult Persistent Asthma: Systematic Review of Clinical Outcomes and Economic Evaluation
November 13, 2009
CADTH’s health technology assessment report on long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination therapy examines the clinical efficacy, safety, and cost-effectiveness of this treatment strategy for adult persistent asthma. This assessment focuses on LABA-I...